Current possibilities of influencing the main cardiovascular risk factors in patients with type 2 diabetes mellitus

Current possibilities of influencing the main cardiovascular risk factors in patients with type 2 diabetes mellitus

Background. Cardiovascular morbidity increases notably among patients with diabetes. A correlation between leptin resistance and cardiovascular risk was found in patients with arterial hypertension and metabolic syndrome. However, there are no data about the influence of empagliflozin on leptin leve...

Full description

Bibliographic Details
Main Authors:	O.Ya. Kobrynska, O.M. Didushko
Format:	Article
Language:	English
Published:	Zaslavsky O.Yu. 2022-12-01
Series:	Mìžnarodnij Endokrinologìčnij Žurnal
Subjects:	diabetes mellitus type 2 cardiovascular risk factors empagliflozin overweight obesity
Online Access:	https://iej.zaslavsky.com.ua/index.php/journal/article/view/1220

Similar Items

Cardiovascular death risk reduction in type 2 diabetes patients with confirmed cardiovascular diseases
by: Е. V. Shlyakhto, et al.
Published: (2018-09-01)

Hypertension as a Risk Factor for Diabetes Mellitus
by: I.P. Romanova, et al.
Published: (2013-10-01)

Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials
by: Yu Jiang, et al.
Published: (2022-03-01)

Elderly patient with complex concomitant cardiovascular disease
by: Vincenzo Cimino, et al.
Published: (2018-08-01)

Study of prevalence of type 2 diabetes mellitus and hypertension in overweight and obese people
by: Abhijit Mandal
Published: (2014-01-01)

Obese and hypertensive elderly patient, with incipient diabetic nephropathy and previous cardiovascular event, long-term treated with secretagogues
by: Andrea Da Porto
Published: (2018-07-01)

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME® trial
by: Takashi Kadowaki, et al.
Published: (2019-05-01)

Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population
by: Asima Khan, et al.
Published: (2022-08-01)

Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial
by: João Pedro Ferreira, et al.
Published: (2020-11-01)

Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes
by: Zsolt Szekeres, et al.
Published: (2023-02-01)

A NEW INDICATION FOR EMPAGLIFLOZIN: TURNING POINT IN THE TREATMENT OF TYPE 2 DIABETES
by: M. V. Amosova, et al.
Published: (2017-12-01)

Associations of concurrent early‐life famine exposure and adulthood obesity with type 2 diabetes mellitus in middle‐aged Chinese
by: Qian Yi, et al.
Published: (2024-02-01)

Efficacy and Safety of Empagliflozin in Type 2 Diabetes Mellitus Saudi Patients as Add-On to Antidiabetic Therapy: A Prospective, Open-Label, Observational Study
by: Fahad M. Althobaiti, et al.
Published: (2022-08-01)

How Do the Different Types of Maternal Diabetes during Pregnancy Influence Offspring Outcomes?
by: Lina Eletri, et al.
Published: (2022-09-01)

Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
by: A. V. Simanenkova, et al.
Published: (2021-07-01)

Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
by: Schernthaner G, et al.
Published: (2017-01-01)

Type 2 diabetes mellitus and chronic kidney disease: modern opportunities for antihyperglycemic therapy
by: O.M. Didushko
Published: (2020-04-01)

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
by: Mafalda Ramos, et al.
Published: (2021-08-01)

Changes from 1986 to 2018 in the prevalence of obesity and overweight, metabolic control and treatment in children with type 1 diabetes mellitus in a Mediterranean area of Southeast Spain
by: María Teresa Pastor-Fajardo, et al.
Published: (2022-05-01)

Inhibitors of the sodium-glucose transporter type 2 and new possibilities for managing vascular age in patients with type 2 diabetes mellitus
by: I. Sh. Khalimov, et al.
Published: (2021-09-01)

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
by: Subodh Verma, et al.
Published: (2021-08-01)

Control of cardiovascular risk in patients with diabetes
by: Yu V Zhernakova, et al.
Published: (2016-09-01)

Control of cardiovascular risk in patients with diabetes
by: Zhernakova Yu.V., et al.
Published: (2016-08-01)

Lifestyle modification program, LIFE is LIGHT, in patients with type 2 diabetes mellitus and obesity: Results from a 48‐week, multicenter, non‐randomized, parallel‐group, open‐label study
by: Gagik R. Galstyan, et al.
Published: (2021-08-01)

Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus
by: Vladimir V. Salukhov, et al.
Published: (2016-12-01)

Overweight elderly patient suffering from multiple comorbidities
by: Sebastiano Bruno Solerte
Published: (2018-07-01)

Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
by: Antonio Ceriello, et al.
Published: (2020-10-01)

How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
by: Agnes Bosch, et al.
Published: (2019-03-01)

Cost-effectiveness of Empagliflozin, in Addition to Metformin, in Patients with Type 2 Diabetes in Italy
by: Edoardo Mannucci, et al.
Published: (2022-12-01)

Type 2 diabetes mellitus and chronic heart failure: new treatment strategies
by: Irina Z. Bondarenko, et al.
Published: (2021-12-01)

Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors
by: Siarhei A. Dabravolski, et al.
Published: (2022-05-01)

Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo‐controlled double‐blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi‐center placebo‐controlled double‐blind randomized trial
by: Atsushi Tanaka, et al.
Published: (2020-11-01)

The relationship of flavonoid intake during pregnancy with excess body weight and gestational diabetes mellitus
by: Mariana de Andrade Balbi, et al.

Does the lipid profile depend on the comorbidity of overweight/obesity and arterial hypertension in patients with type 2 diabetes mellitus?
by: I.V. Vivsiana, et al.
Published: (2021-08-01)

Diabetes: how to manage overweight and obesity in type 2 diabetes mellitus
by: Megan Wesling, et al.
Published: (2022-06-01)

Influence of Visceral Adiposity on Cardiovascular Autonomic Neuropathy in Patients with Type 2 Diabetes Mellitus
by: Eun-Hee Jang, et al.
Published: (2012-08-01)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
by: Moritz Mahling, et al.
Published: (2019-08-01)

Beneficial effects of pomegranate peel extract treatment on anthropometry and body composition of overweight patients with diabetes mellitus type-2: A randomised clinical trial
by: Grabež Milkica, et al.
Published: (2020-01-01)

Cardiovascular risk in type 1 diabetes mellitus
by: Ines Ben Hadj Slama Slim
Published: (2013-01-01)

Does Empagliflozin Modulate Leukocyte–Endothelium Interactions, Oxidative Stress, and Inflammation in Type 2 Diabetes?
by: Francisco Canet, et al.
Published: (2021-07-01)